Bloating is commonly reported in gastroparesis, but its prevalence, impact, and associated factors are uninvestigated. We aimed to quantify the prevalence of bloating in gastroparesis and relate its severity to clinical factors and quality of life.
INTRODUCTION
Manifestations of gastroparesis are varied. Symptoms other than nausea and vomiting may be prominent. Th e validated Gastroparesis Cardinal Symptom Index (GCSI) quantifi es nine symptoms in three subscales -nausea and vomiting, postprandial fullness, and bloating ( 1 ) . Case series characterizing specifi c symptoms in gastroparesis oft en relate bloating to gastric function or response to prokinetic therapy ( 2 ) . Furthermore, greater degrees of bloating and distention in patients with gastroparesis have been associated with poorer responses to therapy ( 3 ) .
Th e characteristics of bloating in functional bowel disorders have been extensively investigated. Prominent bloating in irritable bowel syndrome (IBS) and functional dyspepsia contributes to disease severity and impairs quality of life ( 4, 5 ) . Pathogenic factors for Bloating in Gastroparesis: Severity, Impact, and Associated Factors bloating in these disorders include luminal sensorimotor dysfunction and altered abdominal somatic musculature activity ( 6 -10 ) . Smoking may also contribute to bloating in IBS ( 11 ) . Agents stimulating transit, modulating visceral sensation, or altering gut fl ora treat bloating in the functional disorders ( 12 -15 ) . Th e prevalence of bloating in gastroparesis and the relation of bloating severity to demographic factors, severity of other symptoms, quality of life, gastric and extragastric factors involved in its pathogenesis, and medication use are unexplored.
Demographic information, clinical features, disease-specifi c severity and quality-of-life scores, examination fi ndings, and gastric scintigraphy results from patients with gastroparesis from US academic centers were analyzed to address four aims: (i) quantify the prevalence of bloating and relate bloating severity to demographic factors to test the hypotheses that intensity of bloating is dependent on patient gender and age; (ii) to test the hypotheses that bloating severity correlates with investigator-rated disease severity, intensity of other manifestations of gastroparesis measured by validated symptom surveys (GCSI and Patient Assessment of Upper Gastrointestinal Disorders Symptoms Severity Index (PAGI-SYM)), and quality of life measured by both an upper gut sensorimotor disorder-specifi c survey (Patient Assessment of Upper Gastrointestinal Disorders Quality of Life (PAGI-QOL)) and a more general measure of functional health and well-being (Short Form-36 (SF-36)); (iii) defi ne gastric and extragastric factors potentially pathogenic of bloating to test the hypotheses that bloating severity relates to delayed gastric emptying, lower gut factors, obesity, and smoking; and (iv) relate medication use to bloating severity to test the hypothesis that pharmaceutical factors are associated with this symptom ( 1, 16, 17 ) . Th rough these investigations, we hoped to gain insight into bloating in gastroparesis to provide a foundation for future investigations into the pathogenesis and management of this underappreciated symptom.
METHODS

Patient population
A total of 335 gastroparesis patients were recruited by six centers of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Gastroparesis Clinical Research Consortium into a Gastroparesis Registry from January 2007 through November 2009 (ClinicalTrials.gov Identifi er: NCT00398801). Th e distributions of patients recruited from each clinical center included 39 from the University of Michigan, 95 from Temple University, 65 from Stanford University and its satellite California Pacifi c Medical Center, 64 from the University of Mississippi, and 72 from Wake Forest University. Patients ≥ 18 years old with symptoms of gastroparesis for ≥ 12 weeks (not necessarily contiguous) and with delayed gastric emptying ( > 60 % retention at 2 h and / or > 10 % at 4 h) on 4 h gastric scintigraphy aft er a low-fat meal within 6 months of enrollment were included ( 18 ) . Most patients were referred for specialized care of gastroparesis from providers in the community to expert clinicians at the study centers. Other patients were sent from other physicians within the study centers to the principal investigators at those sites. In most instances, referrals were made seeking second opinions. In some centers, referrals were initiated to gain access to specialized services such as prescription programs for domperidone, endoscopic pyloric botulinum toxin injection, or surgical implantation of gastric stimulator devices. Some patients initiated their own referrals aft er accessing websites describing the Gastroparesis Registry. Exclusion criteria included other conditions potentially explanatory of symptoms (e.g., obstruction, infl ammatory bowel disease, eosinophilic gastroenteritis, neurologic disease, and acute liver or kidney disease); and previous fundoplication, gastric resection, or pyloroplasty.
Institutional review board approval was obtained at Clinical Centers and the Data Coordinating Center. Patients provided written informed consent.
Data acquisition and analysis
Data collection . On enrollment, questionnaires quantifying symptoms of gastroparesis (including bloating) were administered to subjects. During face-to-face interviews, the principal investigator or study coordinator completed the Baseline Medical History questionnaire that queried symptoms, disease profi les, associated conditions, and therapies. Physical examination fi ndings, laboratory profi les, and fi ndings of upper endoscopy (within the previous 12 months) and gastric scintigraphy (within the previous 6 months) were recorded. Patient-reported bloating severity was quantifi ed by extracting the GCSI from the PAGI-SYM questionnaire ( 16 ) . Th e GCSI enumerates 9 symptoms from 0 (no symptoms) to 5 (most severe) ( 1 ). Mean GCSI bloating subscale scores were calculated by averaging the scores for bloating (feeling like you need to loosen your clothes) and stomach or belly visibly larger. For the comparisons of this investigation, patients were stratifi ed by GCSI bloating subscale score into those with the lowest (score 0 -1.9), intermediate (2 -3.9), and highest ( ≥ 4) bloating severity. Th is stratifi cation was made post hoc and the comparisons performed are exploratory in nature. Th ose in the lowest category reported bloating subscale severity ranging from none up to mild severity, whereas those in the intermediate category rated bloating subscale severity ranging from mild up to severe intensity. Subjects in the highest bloating category reported bloating subscale intensity ranging from severe to very severe.
Relation of bloating severity to clinical variables . Demographic variables were gleaned from the Registration and Baseline Medical History forms and included age on Registry enrollment, gender, ethnicity, race, duration of gastroparesis symptoms, and gastroparesis etiology. In all, 116 individuals were deemed to have gastroparesis because of diabetes, whereas 219 patients had gastroparesis of an idiopathic nature based on no previous gastric surgery, no diabetes history, a normal hemoglobin A1c, and no other known etiologies. Patients with conditions other than diabetic or idiopathic gastroparesis were too few in number to undergo meaningful analysis and were excluded.
Gastroparesis severity and quality of life were quantifi ed using several surveys. Investigator-rated severity was queried on Baseline Medical History forms. Grade 1 gastroparesis was defi ned by easily controlled symptoms with maintenance of weight on a regular diet. Grade 2 gastroparesis was defi ned by moderate symptoms
The American Journal of GASTROENTEROLOGY VOLUME 106 | AUGUST 2011 www.amjgastro.com partly controlled by daily medications, but with maintenance of nutrition with dietary modifi cation. Grade 3 gastroparesis was defi ned if symptoms were medication refractory, if frequent physician and emergency department visits or hospitalizations were reported, and / or if oral nutrition was impossible. Th is stratifi cation has been proposed by an expert panel ( 19 ) . Nausea and vomiting and postprandial fullness subscale scores were calculated from the GCSI survey. Disease-specifi c quality of life was assessed by the PAGI-QOL survey, which scores 30 questions and 5 dimensions from 0 (none of the time) to 5 (all of the time) ( 17 ) . Overall PAGI-QOL scores are calculated by taking means of all subscores aft er reversing item scores; thus a mean PAGI-QOL score of 0 represents poor quality of life, whereas 5 refl ects the best life quality. Four physical (physical functioning, role-physical, bodily pain, and general health) and four mental (vitality, social functioning, role-emotional, and mental health) subscores from SF-36 surveys were calculated as additional quality-of-life measures. Th ese SF-36 subscores were combined to form composite Physical Component and Mental Component scores.
Gastric and extragastric factors with potential pathogenic relevance were quantifi ed by selected survey, physical examination, and gastric emptying data. Percentages of patients with selfreported visible distention on the Baseline Medical History form were noted. Upper and lower abdominal pain, constipation, and diarrhea scores from the PAGI-SYM were scored from 0 (no symptoms) to 5 (most severe) ( 16 ) . Body mass index, overweight status (body mass index ≥ 25 kg / m 2 ), waist circumference, hip circumference, and the waist-to-hip circumference ratio were calculated to assess increased girth from luminal gas retention, altered somatic muscle activity, or obesity. Current and past smoking was queried on the Baseline Medical History form. Scintigraphic gastric retention rates at 1, 2, and 4 h were quantifi ed.
Medication use at the time of Registry enrollment was determined from the Baseline Medical History form. Use of prokinetics (metoclopramide, erythromycin, domperidone, clarithromycin, azithromycin, and pyloric botulinum toxin), antiemetics (prochlorperazine, promethazine, trimethobenzamide, meclizine, ondansetron, granisetron, dolasetron, and aprepitant), opiates, probiotics (patients were not queried about probiotics until April 2008; 155 patients are missing this item), neuropathic pain modulators (gabapentin, pregabalin, and topiramate), and antidepressants was queried. Antidepressant use was further stratifi ed into those individuals taking a single agent with signifi cant norepinephrine reuptake inhibitor activity (amitriptyline, nortriptyline, desipramine, imipramine, buproprion, venlafaxine, and duloxetine) vs. a single agent acting via other mechanisms (fl uoxetine, paroxetine, sertraline, citalopram, escitalopram, mirtazapine, and trazodone). Data from 12 patients on more than one antidepressant were not included in this subanalysis.
Statistical analysis
Diff erences in baseline characteristics were compared for those with GCSI bloating subscale scores of 0 -1.9 vs. 2 -3.9 vs. ≥ 4. P values were derived from χ 2 tests for categorical variables, Fisher ' s exact test for categorical variables with small expected numbers, or analysis of variance for continuous variables. All data are reported as mean or percent followed by 95 % confi dence intervals. For categorical variables, the exact binomial 95 % confi dence intervals are presented. As we prespecifi ed variables to be used in the analysis that were hypothesized to be related to bloating, we used two-sided P values with no adjustment for multiple comparisons, which were considered to be statistically signifi cant if P < 0.05. Readers should note that if any of the many possible methods for adjustment for multiple comparisons had been applied, the P values would be higher. Backwards stepwise ordinal logistic regression analysis was used aft er testing that the assumption of a rank outcome was met to identify signifi cant predictors of bloating severity from among candidate predictors at enrollment: Hispanic ethnicity, duration of symptoms, etiology (diabetic, idiopathic), investigator-rated severity (grades 1, 2, and 3), GCSI nausea / vomiting and postprandial fullness scores, PAGI-QOL score, SF-36 physical and mental components, visible distention, individual PAGI-SYM scores, overweight status, waist-to-hip circumference ratio, smoking status (current, previous, never), gastric retention (1, 2, and 4 h), and medication classes (prokinetics, antiemetics, opiates, neuropathic pain modulators, and antidepressants). Th e model was forced to include terms for age at enrollment, gender, and race. Th e P values for removal from the model were > 0.05. Th e ordinal model estimated the relative cumulative odds of a higher bloating severity subset relative to a lower bloating severity subset for each candidate predictor. All analyses were performed using SAS statistical soft ware (version 9. 
RESULTS
Relation of bloating severity to demographic variables
Demographic data from 335 patients were stratifi ed according to bloating severity as measured by the GCSI ( Table 1 ). In all, 80 patients (24 % ) reported GCSI bloating subscale scores from 0 to 1.9, whereas 116 (35 % ) recorded scores of 2 -3.9 and 139 (41 % ) individuals noted bloating subscale scores ≥ 4. Female gender showed signifi cant relation to bloating severity scores ( P < 0.0001). On pairwise comparisons, female predominance was greater in those with GCSI bloating subscale scores 2 -3.9 vs. 0 -1.9 ( P = 0.02) and with scores ≥ 4 vs. 2 -3.9 ( P = 0.02). Th ere were no diff erences in age at enrollment ( P = 0.72), or ethnic ( P = 0.37) or racial ( P = 0.89) composition between groups. Th e percentages of patients reporting short (0 -1.5 years), medium (1.6 -4.9 years), or long ( ≥ 5 years) duration of symptoms were similar in the different bloating severity subsets ( P = 0.59). Diabetics comprised approximately one-third of patients; there were no diff erences in disease etiology between bloating severity groups ( P = 0.49). Relative distributions of type 1 and type 2 diabetics in the subject groups were similar ( P = 0.61).
Relation of bloating severity to gastroparesis severity and quality of life
Bloating was related to investigator-and patient-rated gastroparesis severity. Among all subjects, investigators rated gastroparesis as grade 1 in 12.3 % , grade 2 in 53.8 % , and grade 3 in 33.9 % ( Table 2 ) .
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Investigator-rated severity showed signifi cant diff erences between bloating severity subsets ( P = 0.001). On pairwise comparisons, those with bloating subscale scores ≥ 4 had lower percentages of grade 1 severity vs. those with scores 0 -1.9 ( P = 0.02) and 2 -3.9 ( P = 0.003). Patient-reported nausea and vomiting GCSI subscale scores averaged in the mild to moderate range for each bloating subset. Mean nausea and vomiting scores were higher in those with increased bloating severity ( P = 0.02). Postprandial fullness GCSI subscale scores also showed a relation to bloating severity, being higher in those with greater bloating subscale scores ( P < 0.0001). On pairwise comparisons, patients with bloating subscale scores ≥ 4 had signifi cantly greater nausea and postprandial fullness scores than those with scores 2 -3.9 and with scores 0 -1.9 (all P < 0.05).
Bloating was related to two quality-of-life measures ( Table 2 ). Combining PAGI-QOL scores in all subjects (2.5 ± 1.1) indicated moderately impaired quality of life. Mean PAGI-QOL scores showed inverse correlation with bloating severity, being lowest in those with the highest GCSI bloating subscale scores ( P < 0.0001). On pairwise comparisons, patients with bloating subscale scores ≥ 4 had worse PAGI-QOL scores than those with bloating scores of 2 -3.9 ( P < 0.0001), and those with bloating scores 2 -3.9 had lower PAGI-QOL scores than patients with bloating scores of 0 -1.9 ( P = 0.001). Both the physical and mental component scores of the SF-36 survey showed inverse relation to bloating severity, being lower in patients with high bloating subscale scores (both P < 0.05). On pairwise comparisons for both SF-36 comparisons, patients with bloating subscale scores ≥ 4 had worse scores than those with bloating subscale scores of 0 -1.9 (both P < 0.05).
Relation of bloating severity to potential pathogenic factors
Potential pathogenic factors were compared between bloating subsets ( Table 3 ). Reports of visible distention showed strong in retention at 1 h ( P = 0.57), 2 h ( P = 0.79), or 4 h ( P = 0.47) between bloating severity subsets.
Relation of bloating severity to medication use
Bloating was related to medication use in the three groups ( Table 4 ) . Th ere was a trend to diff erences in antiemetic use between bloating severity groups ( P = 0.06). On pairwise comparisons, patients with bloating subscale scores of 0 -1.9 had less antiemetic use than those with bloating scores of 2 -3.9 ( P = 0.05) and ≥ 4 ( P = 0.03). Probiotics showed a positive association with bloating severity ( P = 0.03). On pairwise comparisons, patients with bloating subscale scores ≥ 4 showed greater probiotic use than those with bloating scores of 2 -3.9 ( P = 0.03). When all antidepressant classes were considered together, there were no differences in use in the three bloating severity subsets ( P = 0.11). However, there were marginally signifi cant diff erences in bloating subset distribution between diff erent antidepressant classes ( P = 0.045). On pairwise comparisons, the percentage of patients on agents with signifi cant norepinephrine reuptake inhibiting activity was signifi cantly higher and the percentage on drugs acting via other pathways was signifi cantly lower in the patients with bloating subscale scores of 0 -1.9 vs. those with scores of 2 -3.9 ( P = 0.02). Th ere were no diff erences in prokinetic medication ( P = 0.72), opiate drug ( P = 0.24), and neuropathic pain modulator use ( P = 0.30) between bloating severity subsets. correlation with bloating severity; distention was not noted by those with the lowest bloating scores but was universally reported by those with the highest bloating subscale scores ( P < 0.0001). On pairwise comparisons, patients with bloating subscale scores ≥ 4 more oft en reported distention than those with bloating scores of 2 -3.9 ( P < 0.0001), and those with bloating scores of 2 -3.9 more frequently noted distention than patients with bloating scores of 0 -1.9 ( P < 0.0001). Upper ( P < 0.0001) and lower ( P < 0.0001) abdominal pain, constipation ( P < 0.0001), and diarrhea ( P = 0.002) scores on the PAGI-SYM survey showed signifi cant positive correlation with bloating severity. On pairwise comparisons, patients with bloating subscale scores ≥ 4 had higher upper and lower abdominal pain, constipation, and diarrhea scores than those with bloating scores of 2 -3.9 and 0 -1.9 (all P ≤ 0.05). Patients with bloating scores 2 -3.9 had higher constipation scores than those with bloating scores of 0 -1.9 ( P = 0.05). Th ere were no diff erences in body mass index ( P = 0.15), percentages of patients who are overweight ( P = 0.18), waist circumference ( P = 0.39), hip circumference ( P = 0.33), and ratios of waist-to-hip circumference ( P = 0.62) between bloating severity groups. Proportions who never smoked, smoked only in the past, and were current smokers were similar in the three groups ( P = 0.37). Pooling all subjects, the 4 h gastric retention averaged 33 % , indicating delayed emptying that was moderately severe. Th ere were no diff erences 
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Ordinal logistic regression analysis to identify predictors of bloating severity
Backward stepwise ordinal logistic regression analysis identifi ed factors predictive of bloating severity subset measured by the GCSI bloating subscale ( Table 5 ). Female gender related to increasing bloating severity (odds ratio (OR) = 2.81, P = 0.001). Among other symptoms, lower abdominal pain severity (OR = 1.37, P < 0.0001) and constipation severity (OR = 1.15, P = 0.04) on the PAGI-SYM related to increasing bloating subscale scores. PAGI-QOL scores related inversely to bloating severity (OR = 0.39, P < 0.0001). Higher SF-36 mental component scores predicted greater bloating scores (OR = 1.03, P = 0.005). Finally, the likelihood of being overweight predicted bloating severity (OR = 1.61, P = 0.04).
DISCUSSION
Most studies focus on nausea and vomiting as the main symptoms of gastroparesis ( 19 ) . However, from single-center series, it is apparent that gastroparesis can present with other symptoms. Bloating is prominent in IBS and functional dyspepsia ( 4,5,7 ). Information on demographic profi les of bloating in these conditions, its impact on disease severity and quality of life, its pathogenesis, and its response to therapy is available ( 7 -15 ) . Little is known about the features of bloating in gastroparesis. Th e present investigation accessed a multicenter registry to investigate characteristics of bloating in gastroparesis. Related data on patients with idiopathic gastroparesis have been presented in other formats in two recent publications from the Gastroparesis Clinical Research Consortium ( 20, 21 ) . Th e strengths of these analyses are with less severe bloating tend to exhibit less severe gastroparesis in general. Likewise, severity of other symptoms of gastroparesis including nausea and vomiting and postprandial fullness measured using GCSI surveys increased with worsening bloating severity. Th ese observations are similar to studies in IBS that report that bloating is bothersome in a majority of IBS patients and is predictive of IBS severity ( 4 ). Disease-specifi c quality of life on the PAGI-QOL showed progressive impairment with increasing bloating severity on both univariate and ordinal logistic regression analyses. Additionally, bloating severity related to reductions in both the physical and mental components of the SF-36 survey on univariate analysis. Decreases in the SF-36 mental component scores with increasing bloating severity parallel other observations from the Gastroparesis Consortium describing increases in measures of depression and anxiety in those with more intense gastroparesis symptoms ( 20 ) . It remains uncertain whether psychological factors are causes or consequences of increased bloating in the present analysis. Curiously, on the multivariate analysis, the mental component of the SF-36 showed a slight but signifi cant increase in quality of life with increasing bloating severity likely secondary to undetermined interactions between SF-36 scores and other variables. In comparison, bloating relates to impaired quality of life on SF-36 testing in functional bowel disease and correlates with impaired energy / fatigue levels and physical functioning in IBS ( 4, 11 ) .
Examination and survey fi ndings were compared to discriminate possible pathogenic factors of bloating in diff erent the number of patients, rigorous inclusion and exclusion criteria, standardized scintigraphy methods, well-validated surveys administered, and careful statistical methods used. As a consequence, this study provides the most detailed evaluation of this symptom in gastroparesis.
Bloating of at least mild severity was reported by a majority of gastroparesis patients (76 % ), similar to reports in IBS and greater than the 20 % reported in general populations ( 4, 5, 7 ) . Severe bloating was noted by 41 % of patients. Bloating is the third most common reason for seeking health care in IBS, and has been reported as the most common gastrointestinal symptom in diabetes ( 4, 22 ) . In this investigation, patients were stratifi ed into three bloating severity subgroups based on GCSI bloating subscale scores. Th is permitted identifi cation of factors associated with severity of this symptom in gastroparesis. Bloating severity showed strong female predominance, similar to reports in IBS ( 4, 5 ) . Distribution of bloating severity was similar in diabetic and idiopathic gastroparesis. Studies suggest that the neuropathology underlying diabetic and idiopathic gastroparesis is diff erent ( 23 ) . Our fi ndings suggest that bloating is not infl uenced by such diff erential neuronal impairment.
In this study, bloating severity was related to symptom severity and quality of life. Investigator-rated gastroparesis severity showed signifi cant diff erences between bloating subgroups. Most prominently, ratings of grade 1 severity were signifi cantly lower in those with the highest bloating intensity subset vs. patients with the lowest bloating severity. Th is observation indicates that individuals 
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Bloating in Gastroparesis gastroparesis subsets. In IBS, distinctions between perceived bloating and visible distention have been made. Distention is absent in diarrhea-predominant IBS; bloating with distention in constipation-predominant IBS relates to prolonged small intestinal and colonic transit ( 7, 24 ) . Bloaters without distention exhibit reduced thresholds for rectal perception, suggesting heightened visceral sensation ( 9, 10 ) . Altered abdominal somatic muscle activity also promotes distention. Patients with dysmotility syndromes exhibit increased abdominal volumes with anterior abdominal wall protrusion and upward diaphragmatic displacement ( 8 ) .
In this study, visible distention reported on the Baseline Medical History form correlated strongly with bloating subscale score severity. Distention was not reported by any patient with the lowest degrees of bloating and was noted universally in those with the highest symptom scores. Th is is not surprising as distention is scored as part of the GCSI bloating subscale. However, what is striking about this analysis is that none of those in the mildest bloating category reported distention, whereas all in the greatest bloating severity category experienced distention. Th is clearcut discrimination should promote further investigation of the luminal and somatic factors responsible for bloating with or without distention in gastroparesis, as has been performed in IBS ( 6 -10 ) . Despite these reports, no diff erences in waist or hip circumferences could be discerned between bloating subgroups. On PAGI-SYM scoring, bloating severity also strongly related to a range of distal gut symptoms in both diabetic and idiopathic patients including lower abdominal pain, constipation, and diarrhea on univariate analysis and lower abdominal pain and constipation on ordinal logistic regression analysis. Th ese observations raise the possibility of associated generalized dysmotility involving extragastric regions underlying the pathogenesis of bloating. Reports of bloating may also be infl uenced by nongaseous factors. As preliminary data suggest that gastroparesis patients are oft en overweight, we hypothesized that bloating severity relates to body weight factors ( 25 ) . Although bloating did not correlate with body mass index on univariate analysis, overweight status predicted bloating severity on ordinal logistic regression analysis. In functional bowel patients, bloating is associated with smoking, possibly because of aerophagia or inhibitory motor eff ects of tobacco ( 11 ) . Smoking did not relate to bloating severity in gastroparesis patients in this study. Gastric retention at diff erent times postprandially was similar in the bloating severity subsets, indicating that this symptom is not infl uenced by degrees of emptying delay. Other studies relating delayed gastric emptying to bloating in gastroparesis, functional dyspepsia, and diabetes provide confl icting results ( 26, 27 ) . In one recent single-center study, bloating scores were greater in patients with delayed vs. normal gastric emptying ( 28 ) . Conversely, rapid emptying has been observed in fat intolerant patients with bloating ( 29 ) . Additional factors related to bloating in functional dyspepsia and diabetes include enhanced phasic fundic contractions, impaired fundic relaxation, altered intragastric distribution, and increased antral diameter ( 6, 20, 30 ) . Future investigations will determine if these regional dysfunctions contribute to bloating in gastroparesis.
Medication use was analyzed in this study to improve understanding of drug classes relating to bloating in gastroparesis. Th is issue is signifi cant as a recent report has related unfavorable responses to therapy of gastroparesis to increases in bloating and visible distention ( 3 ) . Trials quantifying benefi ts of prokinetics on bloating in gastroparesis have shown improvements, exacerbation, or no eff ect ( 2, 19 ) . Serotonin 5-hydroxytryptamine receptor 4 agonists and acetylcholinesterase inhibitors decrease bloating and distention in other functional disorders (5) . Prokinetic use in this study was similar in the bloating severity subsets, indicating possible lack of effi cacy for this symptom. Th ere was a trend to higher antiemetic use in relation to bloating severity. On pairwise comparisons, the diff erence in antiemetic use was statistically signifi cantly higher in those with the most severe vs. the least severe bloating, consistent with the observation that nausea and vomiting severity parallels bloating in gastroparesis. Opiate use was no diff erent in diff erent subgroups, suggesting that narcotics were not pathogenic of bloating. Likewise, neuropathic pain modulators were taken similarly in the three bloating severity subsets. Such pain modulating agents are reported to blunt visceral sensation in IBS, but appear not to infl uence bloating in gastroparesis ( 31 ) . Probiotic use was higher in those with the most severe bloating. However, the numbers of patients on probiotics in this investigation were small regardless of bloating severity. Th us, the utility of probiotic supplementation in gastroparesis warrants further study. In comparison, probiotics decrease gaseous symptoms in IBS likely because they target colonic rather than gastric microbiota ( 13 ) . Gastroparesis is also associated with bacterial overgrowth ( 32 ) . Th is study did not query antibiotic use; further investigation of the benefi ts of antibiotics for bloating in gastroparesis is warranted.
Antidepressants showed intriguing associations with bloating severity in this study. When antidepressants were subcategorized, use of agents with signifi cant norepinephrine reuptake inhibitor activity was marginally higher in those with the lowest bloating subscale scores, whereas use of agents without signifi cant norepinephrine reuptake inhibition was greater in those with higher degrees of bloating severity. From a numerical standpoint, only 10 % of those with relatively mild bloating (GCSI subscale 0 -1.9) on single antidepressants were on non-norepinephrine reuptake inhibitor agents, whereas 24 -40 % of those with more severe bloating (GCSI subscales ≥ 2) were on similar medications. However, as the norepinephrine reuptake inhibitor subset are small, it is not surprising that the P value is marginally signifi cant.
It cannot be determined from our data whether medications with signifi cant norepinephrine reuptake inhibition improve bloating or if other classes (such as selective serotonin reuptake inhibitors) worsen this symptom in gastroparesis. Furthermore, our data do not permit determination of the reason for use of such agents; it is uncertain if antidepressants in diff erent classes were prescribed for psychiatric disease or gastrointestinal symptomatology. Additionally, all of these drugs have other potential mechanisms of action that may underlie any benefi cial eff ects. Norepinephrine reuptake inhibitors blunt aff erent function in functional bowel disorders; their inhibition of perception of bloating in gastroparesis is unproved. Other therapies of gastroparesis such as gastric electrical stimulation may reduce symptoms by inhibiting aff erent transmission ( 33 ) . However, selective serotonin reuptake inhibitors show limited antinociceptive activity, although citalopram and fl uoxetine reportedly reduce bloating in IBS ( 15 ) . Our fi ndings suggest that prospective studies be performed to test if agents with signifi cant norepinephrine reuptake inhibition are benefi cial in patients with severe bloating. Although this exploratory study associated clinical factors with bloating in gastroparesis, there are limitations to these fi ndings. Data were analyzed on enrollment only from a large database that accumulated information relating to broad, diverse range of clinical factors. Although the analyses of this investigation were designed to test several hypotheses, the database itself was constructed to permit analysis of potential associations relating demographic, severity, quality of life, pathogenic, and medication factors to bloating severity subscale categories that were determined post hoc . Additionally, longitudinal follow-up could provide additional data regarding medication benefi ts in reducing bloating. Relation of symptom benefi ts of medication treatment of bloating to improvements in measures of gastroparesis severity and quality of life would strengthen the observations of this investigation. Th ird, in the nondiabetic patients, there is overlap of symptom profi les in those with idiopathic gastroparesis vs. functional dyspepsia. Current clinical defi nitions provided by consensus documents do not permit confi dent discrimination of the two disorders on symptoms alone ( 34 ) . Furthermore, many functional dyspeptics exhibit delayed gastric emptying and could thus be considered to have idiopathic gastroparesis ( 35 ) . Some expert panels have suggested distinguishing the two disorders on the basis of symptom predominance (pain for functional dyspepsia and nausea and vomiting for idiopathic gastroparesis) ( 19 ) . However in a preliminary report, pain predominance was reported in a fi ft h of patients with gastroparesis, both with diabetes and with idiopathic disease ( 36 ) .
Th ese observations suggest that idiopathic gastroparesis and functional dyspepsia are related disorders with heterogeneous defects in sensory, motor, or central nervous system function. Although invasive testing of gastric aff erent and motor function has characterized a range of abnormalities in functional dyspepsia, such testing has been less intensively employed to study idiopathic gastroparesis.
In conclusion, bloating is prevalent in gastroparesis and is severe in many aff ected patients. Bloating severity in gastroparesis relates strongly to female gender and to, a lesser degree, body weight. Patients with greater bloating severity also report increased intensity of other gastroparesis symptoms as well as higher levels of symptoms relatable to the lower gut, suggestive of possible associated extragastric dysmotility. Increasing bloating severity correlates with impaired disease-specifi c quality of life and general measures of physical and mental health and well-being. Bloating does not relate to gastric retention or tobacco use. Antiemetic and probiotic use relates to bloating severity subclass. Antidepressant use may aff ect reports of bloating severity, with reductions in those on agents with signifi cant norepinephrine reuptake inhibition and increases in other classes. Th ese fi ndings provide insight into this underappreciated symptom of gastroparesis and provide the foundation for future investigations into its pathogenesis and management.
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WHAT IS CURRENT KNOWLEDGE
3 Symptoms other than nausea and vomiting are commonly reported by patients with gastroparesis and may be prominent.
3 Bloating is prevalent in functional bowel disorders and has signifi cant impact on disease severity and quality of life in these conditions.
3 The prevalence of bloating in gastroparesis and the relation of its severity to demographic factors, severity of other symptoms, quality of life, gastric and extragastric factors involved in its pathogenesis, and medication use are unexplored.
WHAT IS NEW HERE
